Compulsory licence
5 articles
New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access
“There is no question that these treatments that can save millions of lives must be made universally available at an affordable price.” More
Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C
Position paper for the 67th World Health Assembly, 19–24 May 2014
People living with HCV, HIV/AIDS, people who use drugs, and their advocates, urge United Nations Member States to act with urgency to end the hepatitis C epidemic; it is possible! More
Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
Myths and facts
Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More
Hepatitis C: Gilead Patent on Sofosbuvir Partially Maintained Following MdM Patent Opposition
Paris, 5 October 2016
European Patent Office (EPO) has taken its decision following Médecins du Monde (MdM) patent opposition on Gilead’s sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent. More
The Potential Impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s Hepatitis C Treatment Program
Acceding to trade agreements such as the CPTPP that require increasing intellectual property protection, could compromise Thailand’s hepatitis C program and other national treatment programs reliant on affordable generic medicines. More
